ISIN:FR0013154002

Sartorius Stedim Biotech SA: Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

Retrieved on: 
Vendredi, février 16, 2024

The issuer is solely responsible for the content of this announcement.

Key Points: 
  • The issuer is solely responsible for the content of this announcement.
  • The person making the disclosure is a closely associated person mentioned of article 3.26) of Regulation (EU) No 596/2014 of April 16, 2014 on market abuse.
  • Please give the identity and functions of the person with whom the reporting person has close personal ties.
  • Position / status: Sartorius AG legal entity related to JOACHIM KREUZBURG, CHAIRMAN OF THE BOARD and RENE FABER, CEO
    This notification is an initial notification.

Sartorius Stedim Biotech releases Universal Registration Document 2023

Retrieved on: 
Vendredi, février 16, 2024

Sartorius Stedim Biotech, a leading partner of the biopharma industry, has released its Universal Registration Document 2023 including the Annual Financial Report today.

Key Points: 
  • Sartorius Stedim Biotech, a leading partner of the biopharma industry, has released its Universal Registration Document 2023 including the Annual Financial Report today.
  • Sartorius Stedim Biotech is a leading international partner of the biopharmaceutical industry.
  • The shares of Sartorius Stedim Biotech S.A. are quoted on the Euronext Paris.
  • Sartorius Stedim Biotech regularly expands its portfolio through acquisitions of complementary technologies.

Sartorius Stedim Biotech: Information on Document Availability

Retrieved on: 
Vendredi, février 16, 2024

The issuer is solely responsible for the content of this announcement.

Key Points: 
  • The issuer is solely responsible for the content of this announcement.
  • Sartorius Stedim Biotech Group’s Universal Registration Document 2023 is now available at:
    It contains the following information:
    - Consolidated financial statements for the year ended December 31, 2023
    Sartorius Stedim Biotech is a leading international partner of the biopharmaceutical industry.
  • The shares of Sartorius Stedim Biotech S.A. are quoted on the Euronext Paris.
  • Sartorius Stedim Biotech regularly expands its portfolio through acquisitions of complementary technologies.

Board of Directors of Sartorius Stedim Biotech resolves to propose a dividend of 0.69 euros per share to the Annual Shareholders’ Meeting

Retrieved on: 
Mercredi, février 7, 2024

The Board of Directors of Sartorius Stedim Biotech S.A. resolved at today’s meeting to submit a proposal to the combined Annual Shareholders' Meeting to be held on March 26, 2024, to pay a dividend of 0.69 euros per share for fiscal 2023.

Key Points: 
  • The Board of Directors of Sartorius Stedim Biotech S.A. resolved at today’s meeting to submit a proposal to the combined Annual Shareholders' Meeting to be held on March 26, 2024, to pay a dividend of 0.69 euros per share for fiscal 2023.
  • The Board of Directors also approved the decision to submit to the Annual Shareholders’ Meeting the 2023 results of Sartorius Stedim Biotech which had already been published on a preliminary basis on January 26, 2024.
  • This press release contains forward-looking statements about the future development of the Sartorius Stedim Biotech Group.
  • Sartorius Stedim Biotech assumes no liability for updating such statements in light of new information or future events.